Enliven Therapeutics CFO sells shares price $94,474

BOULDER, CO – Enliven Therapeutics, Inc. (NASDAQ:ELVN), a pharmaceutical firm with a market capitalization of $1.1 billion, noticed its Chief Monetary Officer Benjamin Hohl execute a collection of inventory transactions, in line with a current SEC submitting. On December 27 and December 30, Hohl offered a complete of 4,250 shares of widespread inventory in Enliven Therapeutics, producing a complete of $94,474. The shares had been offered at costs starting from $22.1549 to $22.5061, close to the present buying and selling worth of $22.50. In accordance with InvestingPro knowledge, the inventory has delivered a formidable 61.78% return over the previous 12 months.

Prior to those gross sales, Hohl exercised inventory choices to accumulate 4,250 shares at a worth of $2.48 per share. These transactions had been carried out beneath a Rule 10b5-1 buying and selling plan adopted on June 26, 2023. Following these transactions, Hohl now not holds any shares straight from these specific possibility workout routines. InvestingPro evaluation suggests the inventory is at the moment pretty valued, with analysts setting worth targets between $33 and $42.

Enliven Therapeutics, primarily based in Boulder, Colorado, is concerned in pharmaceutical preparations and continues to be monitored carefully by traders for its government buying and selling actions. The corporate maintains a robust monetary well being profile, with extra cash than debt on its stability sheet and a strong present ratio of 17.44, indicating wonderful liquidity place.

In different current information, Enliven Therapeutics has been receiving optimistic consideration from numerous analyst corporations. BTIG initiated protection on Enliven Therapeutics with a Purchase ranking and a worth goal of $42.00, specializing in the corporate’s improvement of focused tyrosine kinase inhibitors for most cancers remedy. Clear Road additionally assigned a Purchase ranking to Enliven Therapeutics with a $36.00 goal, citing the corporate’s potential within the continual myeloid leukemia remedy market.

Baird elevated its worth goal for Enliven Therapeutics to $40 following promising knowledge from ongoing trials. Jones Buying and selling gave Enliven Therapeutics a Purchase ranking, predicting worldwide peak gross sales of roughly $800 million for ELVN-001 by 2036. H.C. Wainwright maintained a Purchase ranking on Enliven Therapeutics with a gentle worth goal of $37.00, following the presentation of promising Part 1 outcomes for ELVN-001.

These are all current developments for Enliven Therapeutics, an organization that’s advancing two lead tyrosine kinase inhibitors for each strong and liquid cancers. The corporate’s crew consists of main chemists who’ve been instrumental within the improvement of 4 FDA-approved merchandise and have a historical past of profitable acquisitions. Enliven Therapeutics is anticipated to launch key medical knowledge over the following 12-18 months.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.